Drug archive
Denileukin Diftitox (Systemic)
Archived drug information. This USP DI monograph is kept for reference and dates from the mid-2000s. Doses, warnings, interactions and brand names may have changed, and some products are no longer sold. Always follow your prescriber, your pharmacist and the current label, for example on DailyMed.
Category
- Antineoplastic
Description
Denileukin diftitox (DEN-i-loo-kin DIF-ti-toks) is used to treat cutaneous T-cell lymphoma, a rare type of cancer that affects certain white blood cells and causes lesions to develop on the skin.
Denileukin diftitox interferes with the growth of cancer cells, which are eventually destroyed. Since the growth of normal cells may also be affected by the medicine, other effects may also occur. Some of these may be serious and must be reported to your doctor. Some effects may occur after treatment with denileukin diftitox.
Denileukin diftitox is to be administered only by or under the supervision of your doctor or other health care professional. It is available in the following dosage form(s):
- Injection (U.S.)
Brand Names
Some commonly used brand names are:
In the U.S. -
- Ontak
Generic name product may be available in the U.S.
† Not commercially available in Canada.